Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Prognostic impact of Charlson's Age-Comorbidity Index and other risk factors in patients with pancreatic cancer.

Bagni K, Chen IM, Johansen AZ, Dehlendorff C, Jensen BV, Hansen CP, Preus Hasselby J, Holländer NH, Nissen M, Bjerregaard JK, Pfeiffer P, Yilmaz MK, Rasmussen LS, Nielsen SE, Johansen JS.

Eur J Cancer Care (Engl). 2020 Jan 6:e13219. doi: 10.1111/ecc.13219. [Epub ahead of print]

PMID:
31908093
2.

Prognostic Value of Combined Detection of Serum IL6, YKL-40, and C-reactive Protein in Patients with Unresectable Pancreatic Cancer.

Chen IM, Johansen AZ, Dehlendorff C, Jensen BV, Bojesen SE, Pfeiffer P, Bjerregaard JK, Nielsen SE, Andersen F, Holländer NH, Yilmaz MK, Rasmussen LS, Johansen JS.

Cancer Epidemiol Biomarkers Prev. 2020 Jan;29(1):176-184. doi: 10.1158/1055-9965.EPI-19-0672. Epub 2019 Nov 4.

PMID:
31685562
3.

Age favoured overall survival in a large population-based Danish patient cohort treated with anti-PD1 immune checkpoint inhibitor for metastatic melanoma.

Bastholt L, Schmidt H, Bjerregaard JK, Herrstedt J, Svane IM.

Eur J Cancer. 2019 Sep;119:122-131. doi: 10.1016/j.ejca.2019.06.022. Epub 2019 Aug 20.

PMID:
31442816
4.

High-dose interleukin-2 and interferon as first-line immunotherapy for metastatic melanoma: long-term follow-up in a large unselected Danish patient cohort.

Bastholt L, Svane IM, Bjerregaard JK, Herrstedt J, Hróbjartsson A, Schmidt H.

Eur J Cancer. 2019 Jul;115:61-67. doi: 10.1016/j.ejca.2019.03.023. Epub 2019 May 17.

PMID:
31108244
5.

Prospective, single-center implementation and response evaluation of pressurized intraperitoneal aerosol chemotherapy (PIPAC) for peritoneal metastasis.

Graversen M, Detlefsen S, Bjerregaard JK, Fristrup CW, Pfeiffer P, Mortensen MB.

Ther Adv Med Oncol. 2018 Jun 1;10:1758835918777036. doi: 10.1177/1758835918777036. eCollection 2018.

6.

S-1 (Teysuno) and gemcitabine in Caucasian patients with unresectable pancreatic adenocarcinoma.

Winther SB, Bjerregaard JK, Schonnemann KR, Ejlsmark MW, Krogh M, Jensen HA, Pfeiffer P.

Cancer Chemother Pharmacol. 2018 Mar;81(3):573-578. doi: 10.1007/s00280-018-3528-5. Epub 2018 Jan 31.

PMID:
29387963
7.

Automatic treatment planning facilitates fast generation of high-quality treatment plans for esophageal cancer.

Hansen CR, Nielsen M, Bertelsen AS, Hazell I, Holtved E, Zukauskaite R, Bjerregaard JK, Brink C, Bernchou U.

Acta Oncol. 2017 Nov;56(11):1495-1500. doi: 10.1080/0284186X.2017.1349928. Epub 2017 Aug 25.

PMID:
28840767
8.

Incidence of pancreatic cancer in Denmark: 70 years of registration, 1943-2012.

Weble TC, Bjerregaard JK, Kissmeyer P, Vyberg M, Hansen CP, Holländer NH, Johansen C.

Acta Oncol. 2017 Dec;56(12):1763-1768. doi: 10.1080/0284186X.2017.1351036. Epub 2017 Jul 25.

PMID:
28741399
9.

Peritoneal metastasis from pancreatic cancer treated with pressurized intraperitoneal aerosol chemotherapy (PIPAC).

Graversen M, Detlefsen S, Bjerregaard JK, Pfeiffer P, Mortensen MB.

Clin Exp Metastasis. 2017 Jun;34(5):309-314. doi: 10.1007/s10585-017-9849-7. Epub 2017 May 17.

PMID:
28516306
10.

S-1 in combination with docetaxel and oxaliplatin in patients with advanced gastro-esophageal adenocarcinoma: two parallel phase 1/2a studies.

Pfeiffer P, Qvortrup C, Krogh M, Schoennemann K, Vestermark LW, Jensen HA, Bjerregaard JK.

Acta Oncol. 2017 Jan;56(1):46-51. doi: 10.1080/0284186X.2016.1257865. Epub 2016 Dec 2.

PMID:
27911128
11.

Trends in cancer of the liver, gall bladder, bile duct, and pancreas in elderly in Denmark, 1980-2012.

Bjerregaard JK, Mortensen MB, Pfeiffer P; Academy of Geriatric Cancer Research (AgeCare).

Acta Oncol. 2016;55 Suppl 1:40-5. doi: 10.3109/0284186X.2015.1114675. Epub 2016 Jan 15.

PMID:
26767397
12.

Maintenance Therapy With Cetuximab Every Second Week in the First-Line Treatment of Metastatic Colorectal Cancer: The NORDIC-7.5 Study by the Nordic Colorectal Cancer Biomodulation Group.

Pfeiffer P, Sorbye H, Qvortrup C, Karlberg M, Kersten C, Vistisen K, Lindh B, Bjerregaard JK, Glimelius B.

Clin Colorectal Cancer. 2015 Sep;14(3):170-6. doi: 10.1016/j.clcc.2015.03.002. Epub 2015 Mar 25.

PMID:
25956187
13.

Multidisciplinary team conferences promote treatment according to guidelines in rectal cancer.

Brännström F, Bjerregaard JK, Winbladh A, Nilbert M, Revhaug A, Wagenius G, Mörner M.

Acta Oncol. 2015 Apr;54(4):447-53. doi: 10.3109/0284186X.2014.952387. Epub 2014 Oct 7.

PMID:
25291075
14.

[Cancer from the exocrine pancreas].

Bjerregaard JK, Fristrup C, Pfeiffer P, Mortensen PM.

Ugeskr Laeger. 2013 Nov 25;175(48):2941-4. Review. Danish.

PMID:
24629436
15.

MicroRNA biomarkers in whole blood for detection of pancreatic cancer.

Schultz NA, Dehlendorff C, Jensen BV, Bjerregaard JK, Nielsen KR, Bojesen SE, Calatayud D, Nielsen SE, Yilmaz M, Holländer NH, Andersen KK, Johansen JS.

JAMA. 2014 Jan 22-29;311(4):392-404. doi: 10.1001/jama.2013.284664.

PMID:
24449318
16.

Characteristics, therapy and outcome in an unselected and prospectively registered cohort of patients with gastro-oesophageal cancer.

Schønnemann KR, Mortensen MB, Bjerregaard JK, Fristrup C, Pfeiffer P.

Acta Oncol. 2014 Mar;53(3):385-91. doi: 10.3109/0284186X.2013.820839. Epub 2013 Aug 19.

PMID:
23957622
17.

Diagnostic and Prognostic Impact of Circulating YKL-40, IL-6, and CA 19.9 in Patients with Pancreatic Cancer.

Schultz NA, Christensen IJ, Werner J, Giese N, Jensen BV, Larsen O, Bjerregaard JK, Pfeiffer P, Calatayud D, Nielsen SE, Yilmaz MK, Holländer NH, Wøjdemann M, Bojesen SE, Nielsen KR, Johansen JS.

PLoS One. 2013 Jun 26;8(6):e67059. doi: 10.1371/journal.pone.0067059. Print 2013.

18.

In reply to Parlak and Topkan. Re: Prognostic factors for survival and resection in patients with initial nonresectable locally advanced pancreatic cancer treated with chemoradiotherapy.

Bjerregaard JK, Jensen HA, Nielsen M, Pfeiffer P, Mortensen MB.

Int J Radiat Oncol Biol Phys. 2013 Jan 1;85(1):6-7. doi: 10.1016/j.ijrobp.2012.06.001. No abstract available.

PMID:
23236996
19.

Characteristics, therapy and outcome in an unselected and prospectively registered cohort of pancreatic cancer patients.

Bjerregaard JK, Mortensen MB, Schønnemann KR, Pfeiffer P.

Eur J Cancer. 2013 Jan;49(1):98-105. doi: 10.1016/j.ejca.2012.07.017. Epub 2012 Aug 19.

PMID:
22909997
20.

Phase II study of biweekly cetuximab in combination with irinotecan as second-line treatment in patients with platinum-resistant gastro-oesophageal cancer.

Schønnemann KR, Yilmaz M, Bjerregaard JK, Nielsen KM, Pfeiffer P.

Eur J Cancer. 2012 Mar;48(4):510-7. doi: 10.1016/j.ejca.2011.12.005. Epub 2012 Jan 12.

PMID:
22244801
21.

Prognostic factors for survival and resection in patients with initial nonresectable locally advanced pancreatic cancer treated with chemoradiotherapy.

Bjerregaard JK, Mortensen MB, Jensen HA, Nielsen M, Pfeiffer P.

Int J Radiat Oncol Biol Phys. 2012 Jul 1;83(3):909-15. doi: 10.1016/j.ijrobp.2011.09.008. Epub 2011 Dec 13.

PMID:
22172900
22.

Feasibility of FDG-PET/CT imaging during concurrent chemo-radiotherapy in patients with locally advanced pancreatic cancer.

Bjerregaard JK, Fischer BM, Vilstrup MH, Petersen H, Mortensen MB, Hansen CR, Asmussen JT, Pfeiffer P, Høilund-Carlsen PF.

Acta Oncol. 2011 Nov;50(8):1250-2. doi: 10.3109/0284186X.2011.577095. Epub 2011 May 5. No abstract available.

PMID:
21545239
23.

Bevacizumab in combination with cetuximab and irinotecan after failure of cetuximab and irinotecan in patients with metastatic colorectal cancer.

Larsen FO, Pfeiffer P, Nielsen D, Skougaard K, Qvortrup C, Vistisen K, Fromm AL, Jørgensen TL, Bjerregaard JK, Hoegdall E, Jensen BV.

Acta Oncol. 2011 May;50(4):574-7. doi: 10.3109/0284186X.2010.546369.

PMID:
21529301
24.

Biweekly cetuximab and irinotecan as second-line therapy in patients with gastro-esophageal cancer previously treated with platinum.

Schoennemann KR, Bjerregaard JK, Hansen TP, De Stricker K, Gjerstorff MF, Jensen HA, Vestermark LW, Pfeiffer P.

Gastric Cancer. 2011 Aug;14(3):219-25. doi: 10.1007/s10120-011-0031-7. Epub 2011 Mar 17.

PMID:
21409520
25.

Addition of sunitinib to cetuximab and irinotecan in patients with heavily pre-treated advanced colorectal cancer.

Qvortrup C, Jensen BV, Jorgensen TL, Nielsen D, Bjerregaard JK, Pfeiffer P.

Acta Oncol. 2010 Aug;49(6):833-6. doi: 10.3109/0284186X.2010.482104.

PMID:
20615171
26.

Long-term results of concurrent radiotherapy and UFT in patients with locally advanced pancreatic cancer.

Bjerregaard JK, Mortensen MB, Jensen HA, Fristrup C, Svolgaard B, Schønnemann KR, Hansen TP, Nielsen M, Johansen J, Pfeiffer P.

Radiother Oncol. 2009 Aug;92(2):226-30. doi: 10.1016/j.radonc.2009.04.010. Epub 2009 May 10.

PMID:
19435643
27.

The effect of aromatase inhibitors on bone metabolism.

Folkestad L, Bjarnason NH, Bjerregaard JK, Brixen K.

Basic Clin Pharmacol Toxicol. 2009 Jan;104(1):3-10. doi: 10.1111/j.1742-7843.2008.00337.x. Review.

28.
29.

[Chemotherapy and radiotherapy for inoperable pancreatic cancer. A survey of a Cochrane review].

Bjerregaard JK, Pfeiffer P.

Ugeskr Laeger. 2007 Nov 12;169(46):3949-52. Review. Danish. No abstract available.

PMID:
18078646
30.

[Effect of aromatase inhibitors on bone metabolism].

Folkestad L, Bjerregaard JK, Bjarnason NH, Brixen KT.

Ugeskr Laeger. 2007 May 7;169(19):1774-9. Review. Danish.

PMID:
17537350

Supplemental Content

Loading ...
Support Center